Tolerability and Efficacy of RJX in Patients With COVID-19 (RJX)
A Two-part, Two-cohort, Double-blind, Randomized, Placebo-controlled, Multicenter Phase 1/2 Study to Evaluate the Safety, Tolerability and Efficacy of REJUVEINIX (RJX) in Patients With COVID-19
Sponsor: Reven Pharmaceuticals, Inc.
Listed as NCT04708340, this PHASE1/PHASE2 trial focuses on Acute Respiratory Distress Syndrome and COVID-19 and remains ongoing. Sponsored by Reven Pharmaceuticals, Inc., it has been updated 10 times since 2021, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1/PHASE2
Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Unknown Status PHASE1_PHASE2
Status: Active Not Recruiting → Unknown Status
-
Apr 2022 — Apr 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Mar 2022 — Apr 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 5 earlier versions
-
Jun 2021 — Mar 2022 [monthly]
Recruiting PHASE1_PHASE2
-
May 2021 — Jun 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2021 — May 2021 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Mar 2021 — Apr 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Feb 2021 — Mar 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Reven Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .